Epstein-Barr Virus Status And Subsequent Thiopurine Exposure Within A Paediatric Inflammatory Bowel Disease Population

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION(2021)

Cited 2|Views12
No score
Abstract
The use of thiopurine therapy in Epstein-Barr virus (EBV)-naive inflammatory bowel disease (IBD) patients remains controversial due to a risk of EBV-associated complications. We evaluated EBV status and outcomes within our paediatric IBD population over an 8-year period; finding that 217 of 409 (53%) screened patients were seropositive for EBV at IBD diagnosis; that thiopurines were used in 189 of 217 (87%) seropositive and 159 of 192 (83%) seronegative patients (P = 0.22); and that 7 of 192 (4%) previously seronegative patients subsequently tested positive for EBV with 6 of 7 (86%) patients having concurrently recorded thiopurine use. All six patients continued thiopurine with/without a period of cessation; no EBV-associated lymphoproliferative disorders/serious complications were recorded within our cohort. A significant proportion of our patients would not receive thiopurine therapy should their use be avoided in EBV-negative patients (47%) or seronegative males (30%). The small but significant risks of thiopurine treatment must be balanced against the potential benefits of successful IBD management; further research into this is required.
More
Translated text
Key words
children, Epstein-Barr virus, immunomodulator therapy, inflammatory bowel disease
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined